Prognostic factors for hyperdiploid-myeloma: effects of chromosome 13 deletions and IgH translocations
- 2 March 2006
- journal article
- research article
- Published by Springer Science and Business Media LLC in Leukemia
- Vol. 20 (5), 807-813
- https://doi.org/10.1038/sj.leu.2404172
Abstract
Chromosomal hyperdiploidy is the defining genetic signature in 40–50% of myeloma (MM) patients. We characterize hyperdiploid-MM (H-MM) in terms of its clinical and prognostic features in a cohort of 220 H-MM patients entered into clinical trials. Hyperdiploid-myeloma is associated with male sex, kappa immunoglobulin subtype, symptomatic bone disease and better survival compared to nonhyperdiploid-MM (median overall survival 48 vs 35 months, log-rank P=0.023), despite similar response to treatment. Among 108 H-MM cases with FISH studies for common genetic abnormalities, survival is negatively affected by the existence of immunoglobulin heavy chain (IgH) translocations, especially those involving unknown partners, while the presence of chromosome 13 deletion by FISH did not significantly affect survival (median overall survival 50 vs 47 months, log-rank P=0.47). Hyperdiploid-myeloma is therefore a unique genetic subtype of MM associated with improved outcome with distinct clinical features. The existence of IgH translocations but not chromosome 13 deletion by FISH negatively impacts survival and may allow further risk stratification of this population of MM patients.Keywords
This publication has 43 references indexed in Scilit:
- A validated FISH trisomy index demonstrates the hyperdiploid and nonhyperdiploid dichotomy in MGUSBlood, 2005
- Cyclin D dysregulation: an early and unifying pathogenic event in multiple myelomaBlood, 2005
- International Staging System for Multiple MyelomaJournal of Clinical Oncology, 2005
- Genetics and Cytogenetics of Multiple MyelomaCancer Research, 2004
- Clinical and biologic implications of recurrent genomic aberrations in myelomaBlood, 2003
- Continuous absence of metaphase-defined cytogenetic abnormalities, especially of chromosome 13 and hypodiploidy, ensures long-term survival in multiple myeloma treated with Total Therapy I: interpretation in the context of global gene expressionBlood, 2003
- In multiple myeloma, t(4;14)(p16;q32) is an adverse prognostic factor irrespective of FGFR3 expressionBlood, 2003
- Chromosome abnormalities clustering and its implications for pathogenesis and prognosis in myelomaLeukemia, 2003
- Recurrent 14q32 translocations determine the prognosis of multiple myeloma, especially in patients receiving intensive chemotherapyBlood, 2002
- Frequent translocation t(4;14)(p16.3;q32.3) in multiple myeloma is associated with increased expression and activating mutations of fibroblast growth factor receptor 3Nature Genetics, 1997